The combination of dostarlimab and chemotherapy demonstrates robust safety and efficacy in the treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC), according to a study presented at the European Society for Medical Oncology Congress 2023.
This study represented an overall survival (OS) analysis from the phase 2 PERLA trial, which investigators noted was the first global, randomized, double-blind, head-to-head study of 2 PD-1 inhibitors, dostarlimab and pembrolizumab, in NSCLC.
The analysis comprised 243 patients with metastatic NSCLC; documented PD-L1 status; absence of EGFR, ALK, or other actionable genomic aberrations determined locally; an Eastern Cooperative Oncology Group performance status of 0 to 1; and no prior systemic treatment. The population of interest was randomized 1:1 to dostarlimab plus chemotherapy (n=121) or pembrolizumab plus chemotherapy (n=122). The primary end point was objective response rate, and secondary end points included OS and duration of response.
Median OS was 19.4 months (95% CI, 14.5 to not reached) in the dostarlimab plus chemotherapy arm versus 15.9 months (95% CI, 11.6-19.3) in the pembrolizumab plus chemotherapy arm.
“In this follow-up analysis, [dostarlimab plus chemotherapy] continues to demonstrate strong clinical efficacy with no unexpected safety signals. In addition, a numerical trend in OS favoring [dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy] was observed,” the researchers concluded.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.